The company operates as a distributor of pharmaceutical products and medical equipment in Gujarat, while also providing civil construction and infrastructure development services.
The company lacks a durable moat, as evidenced by low net margins of 1.8% and an average ROCE of 5.5%, which is below the typical cost of capital. Its business model relies on low-margin trading and fragmented construction contracts where it lacks significant scale or brand-based pricing power.
Management has prioritized reinvestment into low-return trading activities and related-party ventures. While revenue growth is high, the incremental returns on capital remain poor, and the company has not initiated dividends, choosing to retain modest profits within the business.
The investment collapsed as the paper-thin margins were finally consumed by the realization of bad debts. The qualified audit opinions regarding unconfirmed receivables and payables proved to be the canary in the coal mine; when the related-party entities failed to settle their accounts, the company was forced to write off significant assets, wiping out years of meager profits. The lack of a competitive moat meant the business could not raise prices to offset these losses, and the market eventually re-rated the stock to reflect its true status as a low-return commodity trader with unreliable accounting.
RichFakir rates Maitri Enterprises Ltd's business quality as poor — 26/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Maitri Enterprises Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Maitri Enterprises Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Maitri Enterprises Ltd's fair value is about ₹11 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →